Risk factors for the nosocomial occurrence of imipenem-resistant Acinetobacter baumannii (IRAB) were determined. A case-control study design was used for a comparison of two groups of A. baumannii-positive patients with control patients. Nosocomial IRAB was isolated from the first group of A. baumannii-positive patients, and imipenem-susceptible A. baumannii (ISAB) was isolated from the second group. The control patients were randomly selected in a 4:1 ratio from the same medical or surgical services from which the A. baumannii-positive patients were receiving care when the isolation of IRAB occurred. Risk factors analyzed included demographic variables, comorbid conditions, variables related to hospitalization, and the antimicrobials used. IRAB was isolated from 104 patients, and ISAB was isolated from 387 patients between January and December 2000. The risk factors for IRAB were a previous intensive care unit (ICU) Acinetobacter baumannii strains are becoming increasingly important nosocomial pathogens (3), especially in intensive care units (ICUs), where outbreaks due to this microorganism have been reported (2,5,11). A particular concern has been the frequent multiple antimicrobial resistances exhibited (12,13,14,16). Imipenem and meropenem have retained in vitro activities that are superior to those of other antimicrobials, and in many centers, they are the drug of choice for patients with infections caused by A. baumannii (3). Unfortunately, recent analyses of hospital outbreaks have documented the spread of imipenem-resistant strains (6,8,17). This emergence of imipenem-resistant A. baumannii (IRAB) has become a worldwide problem and a troublesome development that threatens the continued successful treatment of Acinetobacter species infections (1).In our institution, the first case of IRAB bacteremia was detected in August 1997. There was only one case of IRAB bacteremia each year between 1997 and 1998; however, the number of cases increased to five in 1999 and four in 2000. Four cases were in medical wards, three were in the medical ICU, one was in a surgical ward, and three were in surgical ICUs. Since November 2000, we have performed surveillance cultures at ICU admission and isolated patients with multidrug-resistant A. baumannii. As cases of IRAB infection or colonization increased, we reinforced a combination of control measures, such as equipment decontamination, strict attention to hand washing, and isolation procedures. In addition, since March 2001, the use of imipenem has been restricted by requiring approval from an infectious disease specialist.The aim of this study was to identify risk factors for the nosocomial occurrence of IRAB and to contrast those factors with those for imipenem-susceptible A. baumannii (ISAB). Potential risk factors of particular interest were a previous stay in an ICU and antimicrobial drug exposures. The rationale for the study was that previous studies with the same aim had involved smaller numbers of A. baumannii culture-positive patients, thereby limiting the ab...